All Stories

  1. Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour
  2. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  3. Damped Physical Activity and Unstable Sleep: Fitbit-Derived Rest-Activity Phenotypes in Inter-episode Mood Disorders
  4. Transdiagnostic Domain-specific Cognitive Impairment in Inter-episode Mood Disorders and its Relationship with Rest-Activity Phenotypes
  5. Shared genetic and molecular architecture between insulin resistance and cognitive performance
  6. Educational Attainment Polygenic Scores and School Performance in Adolescents With Psychiatric Disorders: A Population-Based Analysis of 86,122 Individuals From the iPSYCH2015 Case-Cohort
  7. Dissecting the pleiotropic genetic architecture of suicide attempt, suicidal ideation, and thirteen correlated traits
  8. Suicidality phenotypes reflect both shared and distinct genetic factors
  9. Risk of all‐cause and cause‐specific mortality, and suicide attempt in people with anxiety and stress‐related disorders: a systematic review, meta‐analysis and meta‐regression analysis of 165 studies
  10. Drug development in autism spectrum disorder: genetic heterogeneity, failed trials, and the case for stratified pharmacotherapy
  11. Sociability and whole-brain resting-state connectivity
  12. Magnetoencephalographic Signatures of Facial Emotion Processing in Schizophrenia and Major Depressive Disorder: A Systematic Review
  13. Shared genetic architecture between psychiatric and insulin-related traits in the general population
  14. Associations between transdiagnostic polygenic liability and antidepressant outcomes in major depressive disorder
  15. Dissecting the pleiotropic genetic architecture of suicide attempt, suicidal ideation, and correlated psychiatric and non-psychiatric traits
  16. Emotion recognition using human avatars in schizophrenia: sex differences between non- immersive and immersive virtual reality
  17. Facial emotion recognition with virtual avatars in schizophrenia and bipolar disorder
  18. Polygenic predisposition to transdiagnostic symptom dimensions and treatment outcomes across psychiatric disorders
  19. Predictors of remission and treatment outcomes in first episode psychosis: insights from the 2-year parma early psychosis programme
  20. Psychiatric-insulin resistance multimorbidity: exploring the joint transcriptomic background
  21. The common genetic and molecular background of insulin resistance and cognitive functions
  22. The genetic link between cognitive domains and insulin resistance
  23. Dissecting the pleiotropic genetic architecture of suicide attempt, suicidal ideation, and thirteen correlated traits
  24. The association of glycemic dysregulation with cognitive decline and structural MRI brain volumes in The Maastricht Study – A role for peripheral inflammation?
  25. Personality domains in early stages of psychosis: a systematic review and meta-analysis
  26. Genome-wide association studies identify 77 loci for suicidality and provide novel biological insights
  27. Polygenic liability to C-reactive protein defines immunometabolic depression phenotypes and influences antidepressant therapeutic outcomes
  28. Schizophrenia Genetics Modulates Clinical Depressive Features
  29. Polygenic predisposition to transdiagnostic symptom dimensions and treatment outcomes across psychiatric disorders
  30. The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts
  31. Psychiatric Risk Governance Across Jurisdictions: A Comparative Analysis of Involuntary Treatment, Community Treatment Orders, and Forensic Mental Health Services
  32. Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness
  33. Factors associated with drug–drug interactions involving citalopram in the UK Biobank
  34. Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
  35. Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data
  36. Correction: Mild motor signs and depression: more than just medication side effects?
  37. Mild motor signs and depression: more than just medication side effects?
  38. Local patterns of genetic sharing between neuropsychiatric and insulin resistance-related conditions
  39. Specific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex
  40. Oropharyngeal microbiota in patients with psychotic disorders: A scoping review on compositional and functional alterations
  41. Predictive coding in neuropsychiatric disorders: A systematic transdiagnostic review
  42. COGNITIVE FUNCTIONS AND PERSONALITY DOMAINS IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS
  43. PERSONALITY DOMAINS AND NEGATIVE SYMPTOMS IN FIRST-EPISODE PSYCHOSIS
  44. The interface of depression and diabetes: treatment considerations
  45. Shared genetics and causal relationship between sociability and the brain’s default mode network
  46. Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review
  47. The gut microbiota's role in bulimia nervosa and binge eating disorder: etiological insights and therapeutic implications from a scoping review
  48. Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder
  49. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
  50. Anhedonia is associated with a specific depression profile and poor antidepressant response
  51. Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases
  52. Unravelling the joint genetic architecture between psychiatic and insulin-related traits in the general population
  53. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  54. Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?
  55. The clinical perspective on late-onset depression in European real-world treatment settings
  56. Mirtazapine blood levels and antidepressant response
  57. Shared familial risk for type 2 diabetes mellitus and psychiatric disorders: a nationwide multigenerational genetics study
  58. Shared genetics linking sociability with the brain's default mode network.
  59. The association of glucose metabolism measures and diabetes status with Alzheimer’s disease biomarkers of amyloid and tau: A systematic review and meta-analysis
  60. Local patterns of genetic sharing challenge the boundaries between neuropsychiatric and insulin resistance-related conditions
  61. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis
  62. The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?
  63. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  64. Genetic relationship between the immune system and autism
  65. Genetic relationship between the immune system and autism spectrum disorder and traits
  66. 33. SHARED GENETICS LINKING SOCIABILITY WITH THE BRAIN'S DEFAULT MODE NETWORK
  67. T13. EPIGENETIC FACTORS INFLUENCING CO-MORBIDITY OF INSULIN-RELATED SOMATIC AND BRAIN DISORDERS
  68. W12. LOOKING BEYOND LABELS: DEFINING DIMENSIONAL PSYCHIATRIC SYMPTOM CLUSTERS WITH INSULIN-RELATED SOMATIC MEASURES BASED ON LARGE POPULATION-BASED GENETIC DATASETS
  69. W16. THE MULTIVARIATE GENETIC ARCHITECTURE OF PSYCHIATRIC AND SOMATIC INSULIN RESISTANCE-RELATED MULTIMORBIDITY
  70. Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta‐analysis
  71. Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
  72. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  73. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
  74. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder
  75. Clinical specificity profile for novel rapid acting antidepressant drugs
  76. Age or age of onset: which is the best criterion to classify late-life depression?
  77. Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
  78. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  79. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns
  80. Association between polygenic risk scores of subcortical brain volumes and antidepressant response: a meta-analysis
  81. Emotional side effects of antidepressants: a systematic review
  82. Epigenetic factors influencing the multimorbidity between somatic and brain-insulinopathies
  83. Pharmacological treatment of psychotic depression: a systematic review and network meta-analysis
  84. What emotional regulation strategies are most related to the affective symptoms of bipolar disorder? A systematic review and network meta-analysis
  85. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review
  86. LOCAL PATTERNS OF SHARED GENETICS AND A GENETIC LATENT FACTOR OF INSULIN RESISTANCE AND NEUROPSYCHIATRIC MULTIMORBIDITY
  87. PSYCHIATRIC AND INSULIN-RELATED SOMATIC MULTIMORBIDITY: INSIGHTS INTO UNDERLYING GENETIC ARCHITECTURE AND BRAIN STRUCTURES INVOLVED
  88. T75. NO LABELS NEEDED: UNDERSTANDING PSYCHIATRIC DISORDERS BASED ON GENETIC TRAITS
  89. Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study
  90. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  91. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs
  92. Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study
  93. The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls
  94. Epigenetics and aetiology of mental illness
  95. Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
  96. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
  97. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder
  98. Depression, antidepressants, and insulin resistance: which link?
  99. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis
  100. Epigenetic Basis of Psychiatric Disorders: A Narrative Review
  101. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder
  102. Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
  103. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features
  104. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  105. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  106. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
  107. Bipolar disorder and comorbid substance use disorder: a machine-learning approach
  108. Genetic dissection of the clinical heterogeneity of major depressive disorder
  109. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  110. Hyperthyroidism and depression: focusing on this complex interplay
  111. The Italian Version of the Brief Assessment of Cognition in Affective Disorders: Performance of Patients with Bipolar Disorder and Healthy Controls
  112. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring – A systematic review and meta-analysis
  113. The cross-link between major depressive disorder and type 2 diabetes mellitus: a review of longitudinal and mendelian randomisation studies
  114. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts
  115. P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  116. W68. A META-ANALYSIS OF POLYGENIC RISK SCORES FOR MOOD DISORDERS, NEUROTICISM, AND SCHIZOPHRENIA IN ANTIDEPRESSANT RESPONSE
  117. TH59. INSULINOPATHIES OF THE BRAIN? GENETIC OVERLAP BETWEEN SOMATIC INSULIN-RELATED AND NEUROPSYCHIATRIC DISORDERS
  118. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis
  119. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  120. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  121. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  122. Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation
  123. P.169 Genetic overlap between somatic insulin-related and neuro-psychiatric disorders
  124. P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  125. P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt
  126. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  127. Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly
  128. P.306 Reduced chemokine ligand 1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  129. M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
  130. Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  131. P.4.01 C-X-C chemokine signalling is implicated in major depressive disorder in a sample of Korean elderly subjects
  132. SA92THE INFLUENCE OF THE SEROTONIN TRANSPORTER GENE 5-HTTLPR POLYMORPHISM ON SUICIDAL BEHAVIORS: A META-ANALYSIS
  133. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis
  134. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis
  135. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans